A5062430369- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Protein Degradation and Inhibitors
- Cutaneous lymphoproliferative disorders research
- Viral-associated cancers and disorders
- Peptidase Inhibition and Analysis
- CNS Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Colorectal Cancer Treatments and Studies
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Medical Imaging Techniques and Applications
- Vascular Tumors and Angiosarcomas
- Lung Cancer Research Studies
- MRI in cancer diagnosis
- Pancreatic and Hepatic Oncology Research
Willamette Valley Cancer Institute and Research Center
2016-2025
The US Oncology Network
2015-2018
McKesson (United States)
2014-2015
Compass Oncology
2012-2014
Oncology Specialists
2013
Nebraska Cancer Specialists
2012
Mayo Clinic in Arizona
2005-2006
Murata (Japan)
2006
PURPOSE In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy combined either lenalidomide (Len) rituximab (R) has demonstrated efficacy acceptable safety. We evaluated the and safety of BV + Len R versus placebo in R/R DLBCL. METHODS ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing Patients received once every weeks, daily, weeks. The primary end point was overall survival...
Summary Spleen tyrosine kinase (Syk) mediates B‐cell receptor signalling in normal and malignant B cells. Entospletinib is an oral, selective Syk inhibitor. monotherapy was evaluated a multicentre, phase 2 study of patients with relapsed or refractory indolent non‐Hodgkin lymphoma mantle cell ( MCL ). Subjects received 800 mg entospletinib twice daily. Forty‐one follicular FL ), 17 lymphoplasmacytoid lymphoma/Waldenström macroglobulinaemia LPL / WM marginal zone MZL ) 39 were evaluated. The...
7514 Background: Dysregulation of MET and VEGFR2 signaling has been observed in NSCLC upregulation implicated resistance to EGFR inhibitors. Cabozantinib (cabo) is an oral, potent inhibitor VEGFR2. A RDT evaluated activity safety 9 tumor types. Here we report on the metastatic cohort which included patients who received prior VEGF pathway targeted therapy. Methods: All eligible (pts) were required have measurable disease at baseline. Pts cabo 100 mg qd over a 12 wk Lead-in stage. Tumor...
IntroductionCabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against MET, vascular endothelial growth factor receptor 2, AXL, ROS1, and RET was assessed in patients non–small-cell lung carcinoma (NSCLC) as part of a phase II randomized discontinuation trial cohorts from 9 tumor types.Patients MethodsPatients received cabozantinib 100 mg/day during 12-week open-label lead-in stage. Those stable disease per Response Evaluation Criteria Solid Tumors version 1.0 at...
535 Background: Dysregulation of MET and VEGF signaling has been implicated in breast cancer development progression, including tumor invasion dissemination. Cabozantinib (cabo) is an oral, potent inhibitor VEGFR2. A RDT evaluated activity safety 9 types, MBC. Methods: Eligible patients (pts) were required to have progressive measurable disease per RECIST. Pts received cabo at 100 mg qd over a 12 wk Lead-in stage. Tumor response (mRECIST) was assessed q6 wks. Treatment ≥ based on response:...
The current study aimed to assess the economic burden of progressive disease among patients with Hodgkin lymphoma (HL) receiving second- or third-line therapy in a large US network community-based practices. This retrospective, observational cohort analysis used electronic health records examine adult classical HL who received chemotherapy between 2007 and 2011. Of 291 observations, 112 had non-progressive (received only one line therapy; LOT1), 114 second-line (LOT2), 65 (LOT3). In LOT2, 49...
BackgroundThe ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral IRd (ixazomib-lenalidomide-dexamethasone) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence and duration while maintaining patients' health-related quality life (HRQoL) improving outcomes.Patients MethodsUS community sites are enrolling non–transplant-eligible patients newly diagnosed multiple myeloma (MM) no evidence progressive...
3069 Background: CD30 is commonly expressed in Hodgkin lymphoma (HL), anaplastic large cell (ALCL), and testicular embryonal carcinoma. Expression of other solid tumors non-lymphomatous malignancies has been reported but not investigated systematically. the target brentuximab vedotin (Adcetris), an antibody drug conjugate (ADC) that approved for treatment patients with relapsed HL systemic ALCL after failure therapies. A study was initiated to determine incidence expression identify who may...
LBA7005 Background: Despite recent advances, there remains a need for novel therapies pts with R/R DLBCL. BV, an anti-CD30 antibody-drug conjugate, has shown efficacy and safety when combined lenalidomide (len) rituximab (R) in heavily pretreated populations (Bartlett 2022; Ward 2022). The double-blind, global phase 3 ECHELON-3 study (NCT04404283) compared BV R+len (R2) vs R2 DLBCL who are ineligible HSCT or CAR T-cell therapy. Here, we present results from the interim analysis (IA) overall...
7528 Background: Tec is the only approved BCMA×CD3 bispecific antibody with personalized, weight-based dosing for triple-class exposed RRMM. In MajesTEC-1 study, showed deep, durable responses and a manageable safety profile. Cytokine release syndrome (CRS) occurred in 72% of pts during Cycles 1-2, 33% had recurrent CRS grade (gr) ≤3 (gr 3, 0.6%). Tocilizumab (Toci) used to manage CRS. separate cohort, who received prophylactic Toci (proToci) experienced less CRS, compared did not (26% vs...
7007 Background: Spleen tyrosine kinase (Syk) is a mediator of B-cell receptor signaling in normal and transformed B-cells. GS-9973 an orally bioavailable, selective inhibitor Syk (Kd 7.6 nM, no other < 100 nM). Methods: This Phase 2 trial enrolled 44 subjects with CLL treated 800 mg BID. Tumor imaging occurred at weeks 8, 16, 24 then every 12. Response was independently evaluated according to Hallek 2008 as modified by Cheson 2012. plasma levels were obtained concurrently chemo/cytokine...